title: [Diagnosis and treatment of retinoblastoma: current strategies for effective tumour control and preservation of vision].
abstract: There are approximately 40 new cases of retinoblastoma in Germany per year. Children in whom the tumour is detected when still intraocular have an excellent overall survival rate (> 95%). However, the prognosis of metastasised retinoblastoma remains poor. About 40% of retinoblastoma patients have tumours in both eyes. For these children in particular it is important to save the eye and visual function as much as possible. There are several options for conservative treatment of localised retinoblastoma including laser coagulation, thermotherapy, cryotherapy, brachytherapy and chemotherapy. In recent years, systemic chemotherapy has become the established standard for primary treatment of intraocular retinoblastoma. In case series, intra-arterial, intravitreal and periocular applications of chemotherapy were also shown to be effective in treating intraocular retinoblastoma. Genetic testing is an integral part of the routine diagnostics of all patients. Mutation analysis of tumour material is invaluable for identification of somatic mutations including mutational mosaicism. Genetic testing also identifies children with heritable retinoblastoma, which represent 50% of cases. These children also have a predisposition for the development of tumours outside of the eye (second primary neoplasm). To adequately address these and other late effects in survivors of retinoblastoma, a multidisciplinary approach is needed that optimises therapy and long-term follow-up. Upcoming multicentre clinical trials will evaluate treatment concepts for localised and metastasised retinoblastoma to improve survival rates and quality of life of children with retinoblastoma. This article was translated and modified and was primarily published in Klin Padiatr 2012; 224: 339-347.
authors.affiliation: Klinik für Kinderheilkunde III, Universitätsklinikum Essen, Germany. petra.temming@uk-essen.de
authors.forename: P
authors.initials: P
authors.lastname: Temming
authors.forename: A
authors.initials: A
authors.lastname: Eggert
authors.forename: N
authors.initials: N
authors.lastname: Bornfeld
authors.forename: W
authors.initials: W
authors.lastname: Sauerwein
authors.forename: S
authors.initials: S
authors.lastname: Göricke
authors.forename: D R
authors.initials: DR
authors.lastname: Lohmann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant; D002648:Child; D018450:Disease Progression; D004333:Drug Administration Routes; D015353:Eye Enucleation; D020022:Genetic Predisposition to Disease; D006801:Humans; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000517:prevention & control*; D011379:Prognosis; D019572:Retinal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012175:Retinoblastoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*